Spinraza Archives -

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with

Biogen looks beyond Spinraza in SMA with Ionis deal

https://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/

Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing

Roche builds evidence for Evrysdi’s benefits in younger SMA patients

https://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded

Biogen plans trial of Spinraza in patients not responding to SMA gene therapy

https://pharmaphorum.com/news/biogen-trialling-spinraza-in-patients-not-responding-to-novartis-sma-gene-therapy/

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision

FDA cues up May verdict for Roche’s SMA challenger risdiplam

https://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/

Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s

NHS chief hails SMA drug deal – and was that a swipe at Vertex?

https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on

PTC shares soar after SMA drug data impresses market

https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/

Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

https://pharmaphorum.com/news/biogen-sees-spinraza-slow-q3/

Spinraza